BMC Gastroenterology
Cure8 research brief
Why This Matters
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but the small numbers and incomplete follow-up mean uncertainty remains.
Who Should Pay Attention
Adults with Crohn's disease, clinicians choosing or sequencing biologics, researchers studying biologic effectiveness, patients on biologics
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study used a prospective registry and propensity-score weighting to compare 56 patients who received anti-TNF after ustekinumab with 117 biologic‑naïve patients starting anti-TNF. Primary endpoints were steroid-free clinical remission at weeks 14 and 52.
At week 14 remission was similar between groups; at week 52 remission appeared higher in the biologic‑naïve group but estimates were imprecise and not statistically significant. Objective endoscopic and intestinal-ultrasound reassessment was done only in subsets, limiting certainty about mucosal healing.
The authors caution that prior exposure is confounded with treatment line, the exposed group was small, and some patients lacked week‑52 data, so the study cannot establish equivalence between strategies. Safety events were reported descriptively without definitive comparisons.
Keep In Mind
The source is a peer-reviewed article abstract in BMC Gastroenterology; the content here is based on the published abstract (not a full independent review). Observational registry data can be confounded by treatment line and selection; subgroup assessments were selective and estimates imprecise.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBMC Gastroenterology
AuthorsJiawei Zhan, Weiyan Feng, Na Diao +8 more
InstitutionSun Yat-sen University
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...